Congress Increases Funding for Type 1 Diabetes Research, But Who Benefits?

On February 3, 2024, Congress approved an increase in funding for Type 1 Diabetes (T1D) research by extending the Special Diabetes Program (SDP). This bipartisan initiative raises annual federal funding from $160 million to $200 million. Since its inception in 1997, the SDP has generated over $3.5 billion for diabetes research, which has led to significant advancements in treatment options. However, the critical question remains: who will truly benefit from this funding boost?

Living with T1D presents daily challenges that require constant management and access to technology. Individuals rely heavily on tools like Continuous Glucose Monitors (CGMs) to avoid life-threatening blood sugar fluctuations. For those fortunate enough to have access to these technologies, such as in Australia where healthcare systems fully subsidize CGMs, the burden of managing this chronic condition is significantly lighter. In contrast, accessing the same technology in the United States can be prohibitively expensive. For example, a monthly supply of CGMs at a local pharmacy can cost as much as $1,599, while the same supplies would cost nothing in Australia.

The SDP has helped fund critical advancements in diabetes care, including CGMs, insulin pumps, and islet cell transplantation. These innovations have transformed daily life for the more than 2 million Americans living with T1D, enabling them to experience fewer dangerous blood sugar swings and a reduced risk of long-term complications. Despite this progress, the disparities in access to these technologies raise important concerns about equity and affordability.

Access to necessary medical devices and treatments remains complicated in the U.S. The costs associated with newer technologies are substantial. For instance, an insulin pump can exceed $8,000 without insurance, and ongoing supplies can add an additional $2,000 to $6,000 annually. Even for those with insurance, structural barriers such as prior authorizations and prescription renewals complicate access. Many individuals in the T1D community face the harsh reality of having to ration insulin due to high costs, forcing them to choose between basic living expenses and essential healthcare.

Compounding these challenges, even FDA-approved technologies are not guaranteed mass distribution, as the National Institutes of Health (NIH), which administers SDP funding, cannot control market access. Social determinants such as race, income, geography, and employment status further influence who can access these life-saving technologies. Studies show that Black T1D patients are less likely to receive baseline technologies like CGMs and insulin pumps compared to their non-Black counterparts, highlighting systemic inequities within the healthcare system.

California is home to a vibrant ecosystem of biomedical innovation, with Silicon Valley at the forefront of health technology development. Stanford University, a key player in this landscape, benefits from federal research funding and contributes to advancements in diabetes treatment. Yet, while lawmakers may advocate for increased research funding, this focus often overshadows the pressing need for reforms in pricing and insurance coverage.

Investment in scientific research is crucial, but it must translate into tangible benefits for patients. The NIH plays a significant role in establishing research priorities, yet without ensuring equitable distribution of new technologies, the gap between those who can afford care and those who cannot may widen. The goal of scientific progress should be to improve population health, not just the health of individuals with access to premium insurance plans.

As the conversation around diabetes research funding continues, it is essential to prioritize equitable access to care. The increased investment in research is a step forward, but it must be accompanied by a commitment to address the barriers that prevent many from benefiting from these innovations. If the ultimate aim is to achieve both better science and fairer health outcomes, equitable access must be treated with the same urgency as the innovation itself.